Oral
Acute bacterial sinusitis
Adult: 500 mg once daily for 10-14 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | or dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Acute bacterial exacerbation of chronic bronchitis
Adult: 500 mg once daily for 7-10 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Pyelonephritis
Adult: 500 mg once daily for 7-10 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Community-acquired pneumonia
Adult: 500 mg once daily or bid for 7-14 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Complicated skin and soft tissue infections
Adult: 500 mg once daily or bid for 7-14 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Complicated urinary tract infections
Adult: 500 mg once daily for 7-14 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
60>10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Uncomplicated cystitis
Adult: 250 mg once daily for 3 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Chronic bacterial prostatitis
Adult: 500 mg once daily for 28 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly.l |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Oral
Treatment and postexposure prophylaxis of inhalation anthrax
Adult: 500 mg once daily for 8 weeks.
Child: ≥6 months weighing <50 kg: 8 mg/kg up to max 250 mg 12 hourly; ≥50 kg: 500 mg 24 hourly. All doses to be given for 60 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Intravenous
Complicated skin and soft tissue infections
Adult: 500 mg once daily or bid for 7-14 days, infused over 60 minutes.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Reconstitution: IV infusion: Dilute with 5% dextrose solution or 0.9% NaCl to a final concentration of 5 mg/mL.
Incompatibility: Solutions containing multivalent cations (e.g. Mg, Ca), heparin, or alkaline solutions.
Intravenous
Community-acquired pneumonia
Adult: 500 mg once daily or bid for 7-14 days, infused over 60 minutes.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Reconstitution: IV infusion: Dilute with 5% dextrose solution or 0.9% NaCl to a final concentration of 5 mg/mL.
Incompatibility: Solutions containing multivalent cations (e.g. Mg, Ca), heparin, or alkaline solutions.
Intravenous
Pyelonephritis
Adult: 500 mg once daily for 7-10 days, infused over 60 minutes.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Reconstitution: IV infusion: Dilute with 5% dextrose solution or 0.9% NaCl to a final concentration of 5 mg/mL.
Incompatibility: Solutions containing multivalent cations (e.g. Mg, Ca), heparin, or alkaline solutions.
Intravenous
Complicated urinary tract infections
Adult: 500 mg once daily for 7-14 days, infused over 60 minutes.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Reconstitution: IV infusion: Dilute with 5% dextrose solution or 0.9% NaCl to a final concentration of 5 mg/mL.
Incompatibility: Solutions containing multivalent cations (e.g. Mg, Ca), heparin, or alkaline solutions.
Intravenous
Chronic bacterial prostatitis
Adult: 500 mg once daily for 28 days, infused over 60 minutes.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Reconstitution: IV infusion: Dilute with 5% dextrose solution or 0.9% NaCl to a final concentration of 5 mg/mL.
Incompatibility: Solutions containing multivalent cations (e.g. Mg, Ca), heparin, or alkaline solutions.
Intravenous
Treatment and postexposure prophylaxis of inhalation anthrax
Adult: 500 mg once daily for 8 weeks, infused over 60 minutes.
Child: ≥6 months weighing <50 kg: 8 mg/kg up to max 250 mg 12 hourly; ≥50 kg: 500 mg 24 hourly. All doses to be given for 60 days.
Renal impairment: Patient on haemodialysis and CAPD: For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly.
CrCl (ml/min) | Dosage Recommendation |
<10 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 48 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
20-50 | For dosing of 250 mg 24 hourly: Initially, 250 mg followed by 125 mg 24 hourly. For dosing of 500 mg 24 hourly: Initially, 500 mg followed by 250 mg 24 hourly. |
<10 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 24 hourly. |
10-19 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 125 mg 12 hourly. |
20-50 | For dosing of 500 mg 12 hourly: Initially, 500 mg followed by 250 mg 12 hourly. |
Reconstitution: IV infusion: Dilute with 5% dextrose solution or 0.9% NaCl to a final concentration of 5 mg/mL.
Incompatibility: Solutions containing multivalent cations (e.g. Mg, Ca), heparin, or alkaline solutions.
Inhalation
Pseudomonal lung infections in cystic fibrosis
Adult: 240 mg bid (12 hourly) via nebuliser for 28 days followed by 28 days treatment-free. Cycle may be repeated according to patient response.
Renal impairment:
CrCl (ml/min) | Dosage Recommendation |
Severe (<20) | Not recommended. |
Ophthalmic
Bacterial conjunctivitis
Adult: As 0.5% solution: Instill 1-2 drops into the affected eye(s) 2 hourly up to 8 times daily during waking hours for days 1-2, then 4 times daily on days 3-5. Treatment duration depends on the severity and type of infection. Usual duration: 5 days.
Child: ≥1 year Same as adult dose.
Ophthalmic
Bacterial corneal ulcer
Adult: As 1.5% solution: Instill 1-2 drops into affected eye(s) every 30 minutes to every 2 hours during waking hours and approx 4 and 6 hours after retiring on days 1-3, then every 1-4 hours while awake thereafter.